FARMINGDALE, N.Y., Nov. 16, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, has entered into a new, three year, exclusive distribution agreement with JPL Medical Co., Ltd. ("JPL"), of Bangkok, Thailand, for the distribution of the BoneScalpel™ Ultrasonic Bone Cutter. The agreement provides JPL with the right to sell throughout Thailand. Included in the agreement are annual minimum purchase requirements. Initial product training is complete and open market sales have begun.
JPL is known as an aggressive marketer of state-of-the-art medical devices, having successfully launched multiple new, high tech products into Thailand, including capital equipment based surgical systems. JPL possesses special expertise in the fields of neurosurgery, spine surgery and orthopedic surgery.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.
"Misonix is very pleased to add JPL to our expanding distribution network in Asia. Their reputation as a quality, specialty distributor of advanced medical products has been well established," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Their commitment to neurosurgery and spine surgery matches Misonix's own focus on these key market segments."About Misonix: Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com. With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.